SELANK

NEUROPEPTIDE

• Molecular Formula : C33H57N11O9
• Molecular Weight: 751.89 g·mol-1
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro

DESCRIPTION

Selank is another ACTH/MSH-like peptide of the melanocortin class most closely related to the analog tufstin. While traditionally prescribed for anxiety and depression, it has been known to be conductive in many other treatments related to immune modulation, anticoagulation, PTSD, ADHD, and metabolic syndromes. Selank has pronounced anxiolytic activity and acts as a stable neuropsychotropic, antidepressant, and anti-stress drug that relieves aggression and fear reaction in different animal species.

Selank also has a nootropic action, which positively influences the formation of memory and learning processes, and marked immunomodulatory activity. Clinical studies have shown that the effect of selank is similar to that of tranquilizers at low doses, but is not accompanied by the unwanted side effects of benzodiazepine tranquilizers such as amnesia, withdrawal, or dependence. Experiments have also demonstrated the effectiveness of Selank in preventing the accumulation of body fat (i.e., weight gain) with simultaneous activation of the functional state of the anticoagulation system in development of the metabolic syndrome. Furthermore, decreased blood glucose levels have been observed with chronic treatment of this peptide. The peptide Selank, like the drug Semax, induces anticoagulant and hyperglycemia effects possibly due to the presence of the same amino acid sequence, Pro-Gly-Pro, in its structure. Thus, Selank can be used as a broad-spectrum therapeutic agent for the treatment of metabolic syndrome.

Often prescribed for: Anxiolytic, Immune improvement, gastric protection, as a preventative weight gain/metabolic syndrome, and with opioid and alcohol withdrawal/dependence.

PROTOCOL

• Content & Potency: 7500mcg/ml provided in a 3ml nasal spray applicator.
• Suggested dosage: Instill two sprays intranasally once daily.

CLINICAL RESEARCH

P-1114 – Rapid and Slow Response During Treatment of Generalized Anxiety Disorder with Peptide Anxiolytic Selank

T. Syunyakov, E.S Teleshova, G.G. Neznamov, V.K.Bochkarev

Introduction: Heptapeptide Selank approved for the treatment of Generalized Anxiety Disorder (GAD). Studies revealed that Selank acts as an anxiolytic with stimulatory and cognitive enhancing properties. Though time to treatment response significantly varied in patients and this issue has not been studied.

Objectives: Individual treatment response analysis in Selank-treated patients with GAD. Aims: To compare clinical state and EEG changes in patients with different time to treatment response to Selank.

Methods: 20 patients aged 24-52 y.o. with GAD according to DSM-IV were included. Selank was administered at the dose 2700 μg/day intranasally. Study utilized valid clinical scales and pharmaco-EEG.